Ninlaro ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1
61	自己免疫性溶血性貧血	1

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03783416 (ClinicalTrials.gov)	June 1, 2019	10/12/2018	SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis	Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.	Relapsing Remitting Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules	Queen Mary University of London	Takeda Pharmaceuticals International, Inc.	Not yet recruiting	18 Years	65 Years	All	72	Phase 1	United Kingdom

61. 自己免疫性溶血性貧血

---

臨床試験数 : 137 /  薬物数 : 127 - (DrugBank : 55) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 153

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03965624 (ClinicalTrials.gov)	September 1, 2019	24/5/2019	Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia	A Prospective Open-label Trial to Assess the Efficacy and Safety of Ixazomib and Dexamethasone in Patients With Refractory Autoimmune Cytopenia	Immune Thrombocytopenia;Warm Autoimmune Hemolytic Anemia	Drug: Ninlaro	Assistance Publique - Hôpitaux de Paris	Takeda Pharmaceuticals International, Inc.	Withdrawn	18 Years	N/A	All	0	Phase 2	France